The purpose of the Journey Study is to evaluate the effectiveness, safety, and tolerability of a study drug
in participants with schizophrenia who did not respond well enough to antipsychotic therapy and to find out how well the study drug works as an add-on therapy.
This study is evaluating the effectiveness of the study drug, valbenazine, compared to a placebo on symptoms of schizophrenia including hallucinations and confused thoughts. Placebos are made of a substance that looks just like the study drug being tested, but they contain no active ingredients.
You may Qualify if:
**There are additional eligibility requirements,
which the study doctor can explain to you**
The total length of participation in the Journey Study is
up to 16 weeks, which includes 7 on-site study visits. This study comprises the following periods:
Copyright © 2023 Health Synergy Clinical Research - All Rights Reserved.
Powered by GoDaddy Website Builder
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.